Century Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 9, 2022, details the results of Century Therapeutics, Inc.'s 2022 Annual Meeting of Stockholders. The meeting was conducted virtually. As of the record date of April 18, 2022, there were 58,831,828 outstanding shares of common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were submitted to a vote of security holders:
- Proposal 1: Election of Class I Directors
- Eli Casdin: Elected with 51,117,169 votes For, 3,296,278 Withheld, and 1,450,563 Broker Non-Votes.
- Osvaldo Flores, Ph.D.: Elected with 53,227,032 votes For, 1,186,415 Withheld, and 1,450,563 Broker Non-Votes.
- Carlo Rizzuto, Ph.D.: Elected with 53,208,059 votes For, 1,205,388 Withheld, and 1,450,563 Broker Non-Votes.
- Proposal 2: Ratification of Independent Registered Public Accountants
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the 2022 fiscal year.
- Votes For: 55,523,112
- Votes Against: 340,683
- Abstentions: 215
- Broker Non-Votes: None
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class I directors (Eli Casdin, Osvaldo Flores, and Carlo Rizzuto) until the 2025 Annual Meeting.
- Confirm the engagement of Ernst & Young LLP for the 2022 fiscal year audit.
- Note the significant number of Broker Non-Votes (1,450,563) recorded for the director elections.
- Review the definitive proxy statement filed on April 21, 2022, for detailed background on the proposals.